BRAF and non-small cell lung carcinoma: There was no significant difference in OS between WT and BRAF-mutated NSCLC patients following monotherapy or combined therapies with ICIs (HR: 0.85; 95% CI, 0.56 to 1.30; p = 0.47, Fig. 6A).